CMB 0.00% 41.0¢ cambium bio limited

Ann: Regeneus to be granted new patent to target pain in Japan, page-2

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 173 Posts.
    lightbulb Created with Sketch. 53
    Bang, bang.
    From inflammation to pain treatment, RGS, through its Progenza platform, now holds multiple patents in Japan for the use of Mesenchymal Stem Cells.
    Then, Sygenus will be added, for the use of stem cells secretions.
    Very good news. This will only strengthen Kyocera's commercial position in the Japanese market.
 
watchlist Created with Sketch. Add CMB (ASX) to my watchlist
(20min delay)
Last
41.0¢
Change
0.000(0.00%)
Mkt cap ! $4.891M
Open High Low Value Volume
41.0¢ 41.0¢ 41.0¢ $121 294

Buyers (Bids)

No. Vol. Price($)
1 294 41.5¢
 

Sellers (Offers)

Price($) Vol. No.
48.0¢ 24 1
View Market Depth
Last trade - 10.02am 08/11/2024 (20 minute delay) ?
CMB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.